DOI: 10.1055/s-00035024

Thrombosis and Haemostasis

References

Pollack Jr CV, Reilly PA, Bernstein R. , et al.
Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran.

Thromb Haemost 2015;
114 (01) 198-205

Download Bibliographical Data

Search in:
Access: